Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
55 hedge funds and large institutions have $5.47M invested in Adaptimmune Therapeutics in 2025 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 24 closing their positions.
37% more call options, than puts
Call options by funds: $37K | Put options by funds: $27K
15% less funds holding
Funds holding: 65 → 55 (-10)
27.73% less ownership
Funds ownership: 43.61% → 15.88% (-28%)
42% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 24
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
80% less capital invested
Capital invested by funds: $27.7M → $5.47M (-$22.2M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$906K |
| 2 |
Jane Street
New York
|
+$385K |
| 3 |
Renaissance Technologies
New York
|
+$298K |
| 4 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$68.6K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$36.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$6.57M |
| 2 |
TSC
Two Seas Capital
Rye,
New York
|
-$5.41M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$4.09M |
| 4 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$1.15M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$1.06M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GC
76
Garde Capital
Seattle,
Washington
| – | -$180 | -750 | Closed |
|
|
T
77
Transce3nd
Kyle,
Texas
| – | -$42 | -175 | Closed |
|
78
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$37 | -153 | Closed |
|
ADAP Hedge Fund Activity: Q3 2025 in Review
55 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q3 2025, worth a combined $5.47M — down 80% from $27.7M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ADAP and 14 opened new positions — a net loss of 10 holders — while 12 trimmed existing stakes and 7 added.
The largest buyer was UBS Group, adding an estimated $906K. The largest seller was EcoR1 Capital, exiting entirely with an estimated $6.57M sold.
- 55 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q3 2025, down from 65 in Q2 2025.
- Funds reported $5.47M of Adaptimmune Therapeutics stock for Q3 2025, down 80% quarter-over-quarter.
- 14 funds opened new Adaptimmune Therapeutics positions in Q3 2025 and 24 closed out, a net change of -10 holders.
- The largest Adaptimmune Therapeutics buyer in Q3 2025 was UBS Group, an estimated $906K added.
- The largest Adaptimmune Therapeutics seller in Q3 2025 was EcoR1 Capital, an estimated $6.57M sold.
Based on aggregated 13F filings for Q3 2025.